{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06106945",
            "orgStudyIdInfo": {
                "id": "D7230C00001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-508590-89-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "AstraZeneca",
                "class": "INDUSTRY"
            },
            "briefTitle": "AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma",
            "officialTitle": "A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma",
            "therapeuticArea": [
                "Other"
            ],
            "study": "as-monotherapy-or-in-combination-with-anticancer-agents-in-participants-with-relapsed-refractory-multiple-myeloma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-11",
            "studyFirstSubmitQcDate": "2023-10-24",
            "studyFirstPostDateStruct": {
                "date": "2023-10-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AstraZeneca",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.",
            "detailedDescription": "This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM. This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents.\n\nThe study includes dose escalation and dose expansion phases. This study will enroll subjects with RRMM who received at least 3 prior lines of treatment including at least one proteasome inhibitor (PI), one immunomodulator (IMiD), and an anti-CD38 antibody. Subjects will be administered AZD0305 intravenously."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma"
            ],
            "keywords": [
                "GPRC5D",
                "ADC",
                "AZD0305",
                "Relapsed Refractory Multiple Myeloma",
                "RRMM",
                "MMAE"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "This protocol has a modular design, with the potential for future treatment arms, study parts, or modules to be added via protocol amendments. Module 1 will include Phase Ia (Dose escalation), and Phase Ib (Dose expansion/optimization).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 84,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AZD0305 monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "Module 1:\n\nPhase Ia: Dose Escalation Phase Ib: Dose Expansion/Optimization AZD0305 will be prescribed at specified dose levels.",
                    "interventionNames": [
                        "Drug: AZD0305"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AZD0305",
                    "description": "AZD0305",
                    "armGroupLabels": [
                        "AZD0305 monotherapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)",
                    "description": "A DLT is defined as any toxicity that occurs from the first dose of study treatment up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes, any death not clearly due to the underlying disease or extraneous causes, pre-defined haematological and non-haematological toxicities",
                    "timeFrame": "From first dose of study treatment until the end of Cycle 1"
                },
                {
                    "measure": "Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of patients with adverse events and serious adverse events by system organ class and preferred term",
                    "timeFrame": "From time of Informed consent to 30 days post end of treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Phase Ia: Objective Response Rate (ORR)",
                    "description": "The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria",
                    "timeFrame": "From first dose of AZD0305 to progressive disease or Initiation of subsequent MM therapy (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Duration of response (DoR)",
                    "description": "The time from the date of first response until date of disease progression or death in the absence of disease progression",
                    "timeFrame": "From the first documented response to confirmed progressive disease or death (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Progression free Survival (PFS)",
                    "description": "The time from first dose until IMWG defined disease progression or death",
                    "timeFrame": "From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Overall Survival (OS)",
                    "description": "The time from the date of the first dose of study treatment until death due to any cause",
                    "timeFrame": "From first dose of AZD0305 to death (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC)",
                    "description": "Area under the plasma concentration-time curve",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax)",
                    "description": "Maximum observed plasma concentration of the study drug",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)",
                    "description": "Time to maximum observed plasma concentration of the study drug",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Pharmacokinetics of AZD0305: Clearance",
                    "description": "A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2)",
                    "description": "Terminal elimination half-life",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ia: Immunogenicity of AZD0305",
                    "description": "The number and percentage of participants who develop ADAs",
                    "timeFrame": "From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Objective Response Rate (ORR)",
                    "description": "The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria",
                    "timeFrame": "From randomization to progressive disease or Initiation of subsequent MM therapy (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Duration of response (DoR)",
                    "description": "The time from date of first response until date of disease progression or death in the absence of disease progression",
                    "timeFrame": "From randomization to confirmed progressive disease or death (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Progression free Survival (PFS)",
                    "description": "The time from randomization until IMWG defined disease progression or death",
                    "timeFrame": "From randomization to progressive disease or death in the absence of disease progression (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Overall Survival (OS)",
                    "description": "The time from randomization until death due to any cause",
                    "timeFrame": "From randomization to death (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC)",
                    "description": "Area under the plasma concentration-time curve",
                    "timeFrame": "From randomization, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax)",
                    "description": "Maximum observed plasma concentration of the study drug",
                    "timeFrame": "From randomization, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)",
                    "description": "Time to maximum observed plasma concentration of the study drug",
                    "timeFrame": "From randomization, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Pharmacokinetics of AZD0305: Clearance",
                    "description": "A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time",
                    "timeFrame": "From randomization, at predefined intervals throughout the administration of AZD0305 (approximately 2 years"
                },
                {
                    "measure": "Phase Ib: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2)",
                    "description": "Terminal elimination half-life",
                    "timeFrame": "From randomization, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                },
                {
                    "measure": "Phase Ib: Immunogenicity of AZD0305",
                    "description": "The number and percentage of participants who develop ADAs",
                    "timeFrame": "From randomization, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Principal Inclusion Criteria:\n\n* Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.\n* Eastern Cooperative Oncology group (ECOG) performance status of \u2264 2.\n* Documentation of Multiple Myeloma (MM) as defined by International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma. Site should ensure that Multiple Myeloma diagnosis is confirmed in accordance with the IMWG Diagnostic Criteria.\n* Participants must have one or more of the following measurable disease criteria:\n\n  1. Serum M-protein level \u2265 0.5 g/dL.\n  2. Urine M-protein level \u2265 200 mg/24h.\n  3. Serum immunoglobulin free light chain \u2265 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.\n* Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP.\n* Participants must have received at least 3 prior lines of treatment which include a proteasome inhibitor (e.g., bortezomib), an immunomodulator (e.g., lenalidomide), and an anti-CD38 antibody (e.g., daratumumab).\n\nPrincipal Exclusion Criteria:\n\n* Participants exhibiting clinical signs of central nervous system involvement of MM.\n* Participants with known COPD, or previous history of ILD.\n* Participants with known moderate or severe persistent asthma within the past 5 years, or uncontrolled asthma of any classification.\n* Participants who have severe cardiovascular disease which is not adequately controlled.\n* Participants who have a history of immunodeficiency disease.\n* Participants with peripheral neuropathy \u2265 Grade 2.\n* Primary refractory MM.\n* Participants who have previously received anti-GPRC5D or MMAE-containing treatment.\n* Participants who have previously received allogenic stem cell transplant, or participant has received autologous stem cell transplant within 3 months before the first dose of study intervention.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AstraZeneca Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-877-240-9479",
                    "email": "information.center@astrazeneca.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92618",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "zip": "3000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Perth",
                    "zip": "WA 6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.95224,
                        "lon": 115.8614
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Hamilton",
                    "state": "Ontario",
                    "zip": "L8V 5C2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.25011,
                        "lon": -79.84963
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Beijing",
                    "zip": "100044",
                    "country": "China",
                    "geoPoint": {
                        "lat": 39.9075,
                        "lon": 116.39723
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Changsha",
                    "zip": "410013",
                    "country": "China",
                    "geoPoint": {
                        "lat": 28.19874,
                        "lon": 112.97087
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Guangzhou",
                    "zip": "510060",
                    "country": "China",
                    "geoPoint": {
                        "lat": 23.11667,
                        "lon": 113.25
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Shenyang",
                    "zip": "110004",
                    "country": "China",
                    "geoPoint": {
                        "lat": 41.79222,
                        "lon": 123.43278
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Lille",
                    "zip": "59037",
                    "country": "France",
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nantes",
                    "zip": "44000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21725,
                        "lon": -1.55336
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "WITHDRAWN",
                    "city": "Freiburg",
                    "zip": "79106",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 47.9959,
                        "lon": 7.85222
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Hamburg",
                    "zip": "20246",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 53.57532,
                        "lon": 10.01534
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "L\u00fcbeck",
                    "zip": "23538",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 53.86893,
                        "lon": 10.68729
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "N\u00fcrnberg",
                    "zip": "90419",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.45421,
                        "lon": 11.07752
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Wuerzburg",
                    "zip": "97080",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.79391,
                        "lon": 9.95121
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Kashiwa",
                    "zip": "277-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.86224,
                        "lon": 139.97732
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Nagoya-shi",
                    "zip": "467-8602",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.18147,
                        "lon": 136.90641
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Yamagata-shi",
                    "zip": "990-9585",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 38.23333,
                        "lon": 140.36667
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Madrid",
                    "zip": "28027",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31005",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",
            "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",
            "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}